News

Worldwide CAR-T Cell Therapy Market Size to Reach $8.92 billion by 2026, growing at a CAGR of 34.5%

CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report By Target Antigen (CD19/CD22, BCMA, Others); By Indication (Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Follicular Lymphoma (FL), Others); By Regions: Segment Forecast, 2020 – 2026

The Global CAR-T Cell Therapy Market is anticipated to grow at a CAGR of 34.5% during the forecast period 2020-2026. The global market was valued around $482.2 million in the year 2019 and the market is expected to reach $8.92 billion by the end of the year 2026.

CAR-T Cell Therapy is an acronym form of Chimeric Antigen Receptor-T cell therapy. It is a novel therapeutic treatment that comprise of reengineering cancer process of white blood cells of patients. CAR-T cell therapy is used to treat patients with hematologic cancer or blood cancer specifically for non-Hodgkin lymphomas or acute lymphoblastic leukemia.

GET FREE SAMPLE COPY @ https://www.reportocean.com/industry-verticals/sample-request?report_id=5124

The CAR-T cell therapy industry is analyzed to be dynamic from nature and the market players are aggressively competing with each other to gain majority of the market share in Europe and the United States. Moreover, the key players are focusing on research and development, for instance, as per the market study, Celgene will file for the FDA approval of bb2121 (idecabtagene vicleucel) in myeloma and CAR-Ts lisocabtagene maraleucel in lymphoma. CAR-T is majorly leading the cellular therapies stage to create vast evolution in the oncology sector and supporting the major breakthroughs of immuno-oncology.

Segmentation Overview of the Global CAR-T Cell Therapy Market

The Worldwide CAR-T Cell Therapy Market is segmented on the basis of Target Antigen and Indication. These market segments are further categorized into sub-segments to study the market in detail.

The Target Antigen Segment of the Global CAR-T Cell Therapy Market is Sub-Segmented into:

  • BCMA (B-Cell Maturation Antigen)
  • CD19/CD22
  • Others (LewisY, IL13Ra2, NKR-2, PSCA, EGFRvIII, ROR1, L1CAM and MUC16)

The Indication Segment of the Global CAR-T Cell Therapy Market is Sub-Segmented into:

  • Follicular Lymphoma (FL)
  • Multiple Myeloma (MM)
  • Chronic Lymphocytic Leukemia (CLL)
  • Acute Lymphoblastic Leukemia (ALL)
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Others

Geographical Overview of the Global CAR-T Cell Therapy Market

On the basis of geographical segmentation, the global CAR-T Cell therapy market was studied across North America (U.S., Canada); Europe (Germany, UK, France); Asia Pacific (China, India, Japan); Latin America (Brazil, Mexico); Middle East & Africa. As per the analysis, the United States accounted as the dominating region in the global CAR-T Cell Therapy market and that in turn impact the North America market, it is followed by European market considering the market growth over the forecast period. The growth of the US regional market is due to increasing R&D programs and ongoing regulatory approvals.

Key Market Players Insights

Sangamo Therapeutics, Inc. (US), Johnson & Johnson (US), Nanjing Legend Biotechnology Co., Ltd. (China), Noile-Immune Biotech (Japan), Bellicum Pharmaceuticals, Inc. (US), Celyad (Belgium), Caribou Biosciences, Inc. (US), Novartis International AG (Swiss), Intellia Therapeutics (US), Amgen Inc. (US), Mereck KGaA (Germany), Pfizer Inc. (US), Servier Laboratories (France), Cellectis (France), Gilead Sciences, Inc. (US), Celgene Corporation (US) and Bluebird Bio (US) among others are some major players included in the research study of the global CAR-T Cell Therapy market. Pharma and Biotech companies among the mentioned list are highly focusing to secure the dominant position in the global market.

Table of Content
1. Overview and Scope
1.1. Research goal & scope
1.2. Research assumptions
1.3. Research Methodology
1.3.1. Primary data sources
1.3.2. Secondary data sources
1.4. Key take-aways
1.5. Stakeholders
2. Executive Summary
2.1. Market Definition
2.2. Market Segmentation
3. CAR-T Cell Therapy Market – Premium Insights
3.1. CAR-T Cell Therapy– Industry snapshot
3.2. CAR-T Cell Therapy- Ecosystem analysis
3.3. CAR-T Cell Therapy Market dynamics
3.3.1. CAR-T Cell Therapy– Market Forces
3.3.1.1. CAR-T Cell Therapy Market driver analysis
3.3.1.2. CAR-T Cell Therapy Market restraint/challenges analysis
3.3.1.3. CAR-T Cell Therapy Market opportunity analysis
3.4. Industry analysis – Porter’s five force analysis
3.5. CAR-T Cell Therapy Market PEST analysis, 2019
3.6. CAR-T Cell Therapy Industry trends
3.7. Competitive Ranking Analysis
3.8. Timeline of CAR-T Cell Therapy Development
3.9. CAR-T Cell Manufacturing Process
3.10. Side-effects of CAR-T Cell
3.11. Antigens targeting solid tumors
3.12. Clinical trials Landscape for CAR-T
3.13. Commercial Landscape (Mergers & Acquisitions, Partnerships & Collaborations)
3.14. New Innovations in CAR-T therapies
4. CAR-T Cell Therapy Market Size and Forecast 2017 – 2026 by Target Antigen
4.1. Key findings
4.2. CD19/CD22
4.2.1. Global CD19/CD22 market estimates & forecast, 2017 – 2026
4.2.2. Global CD19/CD22 market estimates & forecast, by region, 2017 – 2026
4.3. BCMA (B-Cell Maturation Antigen)
4.3.1. Global BCMA market estimates & forecast, 2017 – 2026
4.3.2. Global BCMA market estimates & forecast, by region, 2017 – 2026
4.4. Others (MUC16, L1CAM, ROR1, EGFRvIII, PSCA, NKR-2, IL13Ra2, LewisY)
4.4.1. Global Other Target Antigen market estimates & forecast, 2017 – 2026
4.4.2. Global Other Target Antigen market estimates & forecast, by region, 2017 – 2026
5.  CAR-T Cell Therapy Market Size and Forecast by Indication
5.1. Key findings
5.2. Diffuse Large B-Cell Lymphoma (DLBCL)
5.2.1. Global DLBCL market estimates & forecast, 2017 – 2026
5.2.2. Global DLBCL market estimates & forecast, by region, 2017 – 2026
5.3. Acute Lymphoblastic Leukemia (ALL)
5.3.1. Global ALL market estimates & forecast, 2017 – 2026
5.3.2. Global ALL market estimates & forecast, by region, 2017 – 2026
5.4. Chronic Lymphocytic Leukemia (CLL)
5.4.1. Global CLL market estimates & forecast, 2017 – 2026
5.4.2. Global CLL market estimates & forecast, by region, 2017 – 2026
5.5. Multiple Myeloma (MM)
5.5.1. Global MM market estimates & forecast, 2017 – 2026
5.5.2. Global MM market estimates & forecast, by region, 2017 – 2026
5.6. Follicular Lymphoma (FL)
5.6.1. Global FL market estimates & forecast, 2017 – 2026
5.6.2. Global FL market estimates & forecast, by region, 2017 – 2026
5.7. Others
5.7.1. Global Other indications market estimates & forecast, 2017 – 2026
5.7.2. Global Other indications market estimates & forecast, by region, 2017 – 2026
6. CAR-T Cell Therapy Market Size and Forecast by Regions
6.1. Key findings
6.2. U.S.
6.2.1. U.S. CAR-T Cell Therapy Market by Target Antigen, 2017-2026
6.2.2. U.S. CAR-T Cell Therapy Market by Indication, 2017 – 2026
6.3. Europe
6.3.1. Europe CAR-T Cell Therapy Market by Target Antigen, 2017 – 2026
6.3.2. Europe CAR-T Cell Therapy Market by Indication, 2017 – 2026
6.4. Japan
6.4.1. Japan CAR-T Cell Therapy Market by Target Antigen, 2017 – 2026
6.4.2. Japan CAR-T Cell Therapy Market by Indication, 2017 – 2026
6.5. Rest of the World
6.5.1. RoW CAR-T Cell Therapy Market by Target Antigen, 2017 – 2026
6.5.2. RoW CAR-T Cell Therapy Market by Indication, 2017 – 2026
7. Company Profiles
7.1. Amgen Inc. (US)
7.1.1. Overview
7.1.2. Financials
7.1.3. Product Benchmarking
7.1.4. Recent Developments
7.2. Bellicum Pharmaceuticals, Inc. (US)
7.2.1. Overview
7.2.2. Financials
7.2.3. Product Benchmarking
7.2.4. Recent Developments
7.3. Bluebird Bio (US)
7.3.1. Overview
7.3.2. Financials
7.3.3. Product Benchmarking
7.3.4. Recent Developments
7.4. Caribou Biosciences, Inc. (US)
7.4.1. Overview
7.4.2. Financials
7.4.3. Product Benchmarking
7.4.4. Recent Developments
7.5. Celgene Corporation (US) (acquired by Bristol-Myers Squibb)
7.5.1. Overview
7.5.2. Financials
7.5.3. Product Benchmarking
7.5.4. Recent Developments
7.6. Cellectis (France)
7.6.1. Overview
7.6.2. Financials
7.6.3. Product Benchmarking
7.6.4. Recent Developments
7.7. Celyad (Belgium)
7.7.1. Overview
7.7.2. Financials
7.7.3. Product Benchmarking
7.7.4. Recent Developments
7.8. Gilead Sciences, Inc. (US)
7.8.1. Overview
7.8.2. Financials
7.8.3. Product Benchmarking
7.8.4. Recent Developments
7.9. Intellia Therapeutics (US)
7.9.1. Overview
7.9.2. Financials
7.9.3. Product Benchmarking
7.9.4. Recent Developments
7.10. Johnson & Johnson (US)
7.10.1. Overview
7.10.2. Financials
7.10.3. Product Benchmarking
7.10.4. Recent Developments
7.11. Mereck KGaA (Germany)
7.11.1. Overview
7.11.2. Financials
7.11.3. Product Benchmarking
7.11.4. Recent Developments
7.12. Nanjing Legend Biotechnology Co., Ltd. (China)
7.12.1. Overview
7.12.2. Financials
7.12.3. Product Benchmarking
7.12.4. Recent Developments
7.13. Noile-Immune Biotech (Japan)
7.13.1. Overview
7.13.2. Financials
7.13.3. Product Benchmarking
7.13.4. Recent Developments
7.14. Novartis International AG (Swiss)
7.14.1. Overview
7.14.2. Financials
7.14.3. Product Benchmarking
7.14.4. Recent Developments
7.15. Pfizer Inc. (US)
7.15.1. Overview
7.15.2. Financials
7.15.3. Product Benchmarking
7.15.4. Recent Developments
7.16. Sangamo Therapeutics, Inc. (US)
7.16.1. Overview
7.16.2. Financials
7.16.3. Product Benchmarking
7.16.4. Recent Developments
7.17. Servier Laboratories (France)
7.17.1. Overview
7.17.2. Financials
7.17.3. Product Benchmarking
7.17.4. Recent Developments

Request for [email protected] https://www.reportocean.com/industry-verticals/sample-request?report_id=5124

Buy this premium research [email protected] https://www.reportocean.com/industry-verticals/details?report_id=5124

About Report Ocean:

We are the best market research reports provider in the industry. Report Ocean believe in providing the quality reports to clients to meet the top line and bottom line goals which will boost your market share in today’s competitive environment. Report Ocean is “one-stop solution” for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:

Report Ocean
Name: Nishi Sharma
Email: [email protected]
Address: 500 N Michigan Ave, Suite 600, Chicago, IIIinois 60611 – UNITED STATES
Tel: +1 888 212 3539 (US – TOLL FREE)
Website: https://www.reportocean.com/
Blog: https://reportoceanblog.com/
Business-news: http://thesmartbusinessnews.com/

About the author

Sharan Stone

Sharan Stone

Sharan comes to Market Research Tab with more than 7 years of experience as an editor. Sharan has his fingers firmly placed on the pulse of the business world and he covers retail, construction, and other industries as an editor for Market Research Tab. Email: [email protected]

More News

Need Your Support

Please Support Us to publish free guest post

Support

Contact

Market Research Tab Inc.
600 B Street Suite 300,
San Diego CA 92101.